로딩 중…
지수 로딩 중…
지놈앤컴퍼니
314130· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,885-7.31%
2026-06-19
Price Chart
지놈앤컴퍼니+85.39%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 220.34B KRW |
| Revenue | 24.02B KRW |
| Net Income | -7.37B KRW |
| Total Assets | 174.35B KRW |
| Net Assets | 114.23B KRW |
| Employees | 102 |
| Value | |
| P/B | 1.93x |
| P/S | 9.18x |
| FCF Yield | -8.47% |
| Profitability | |
| ROE | -6.45% |
| ROA | -4.23% |
| Op. Margin | -119.19% |
| Revenue Growth | -8.99% |
| Financial Health | |
| Debt Ratio | 152.63% |
| Total Debt | 23.64B KRW |
| FCF | -18.67B KRW |
| Cash | 47.13B KRW |
| Current Ratio | 1.49x |
| Performance | |
| 1Y Return | 85.39% |
| 1M Return | -24.03% |
| From 52W High | -52.01% |
| 1Y MDD | -51.40% |
| Trading | |
| Volume | 443,098 shares |
| Foreign Own. | 3.28% |
| Per Share | |
| EPS | -142 KRW |
| BPS | 2,363 KRW |
Company Info
Established in 2015, this global new drug development specialized company went public on KOSDAQ in 2020 and subsequently acquired the management rights of List Labs, a US microbiome CDMO company. Leveraging its Genocle new drug development platform, it researches and develops anticancer drugs and microbiome medicines. The company also operates CDMO, microbiome cosmetics, and health functional food businesses, aiming for integrated pharmaceutical company growth through clinical data-based new drug development and technology transfer commercialization.